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integrated chronic care approach in patients with atrial fibrillation compared to
usual care. The objective of the present study is to assess cost-effectiveness of this
nurse-led care program versus usual care.METHODS:A cost effectiveness analysis
was undertaken alongside the randomized controlled trial in which 712 patients
were included at the Maastricht University Medical Centre, Maastricht, The Neth-
erlands, and allocated to nurse-led care or usual care. Nurse-led care implied
guideline adherent management, steered by dedicated software and supervised by
cardiologists. Usual care was regular outpatient care performed by cardiologists. A
cost per lifeyear as well as a cost per QALY analysis was performed, both from a
hospital perspective. QALYs were based on scores of the Short Form 36 question-
naire (SF-36), converted to utility scores by extracting the Short Form 6D (SF-6D). All
unit prices were supplied by the hospital’s financial department, except for prices
for medication, which were taken from the Dutch Pharmacotherapeutic Compass.
Results represented the costs and effects for a 12 months follow-up period.
RESULTS: The nurse-led care program was associated with slightly more lifeyears
and QALYs at a lower cost. Specifically, the nurse-led program contributed to 0.086
QALY gains with a reduced cost of € 1102.77 per patient and a gain of 0.02 life years
with a reduced cost of € 731.62 per patient. Therefore, the nurse-led program would
be considered dominant. In fact, for all the possible values of willingness to pay for
a QALY the nurse-led program is considered to be more likely cost effective than
the care as usual. CONCLUSIONS: The cost-effectiveness analysis in the present
study demonstrated that a nurse-led integrated care approach is very likely a cost-
effective management strategy for patients with atrial fibrillation.
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OBJECTIVES: To demonstrate the lowest expected cost of the interventions for the
treatment of insomnia in elderly after considering the various costs and utilities
associated with adverse events; falls in particularly using a decision tree.
METHODS: A decision tree was used to estimate the lowest expected cost and
cost-effectiveness of two interventions with untreated elderly population suffering
from insomnia. The economic analysis estimates the average total cost of treat-
ment with benzodiazepines and cognitive behavioural therapy plus the cost asso-
ciated with adverse events due to benzodiazepines and cognitive behavioral ther-
apy, based on published data sources, and average QALYs lost due to various
adverse events associated with use of benzodiazepines.Incremental cost-utility
ratio (ICUR) was calculated to estimate the additional costs of cognitive behavioural
therapy (over benzodiazepines) associated with the use of cognitive behavioural
therapy to achieve a gain of one additional QALY (over benzodiazepines). RESULTS:
Ranking analysis of different strategies revealed that cognitive behavioural ther-
apy is 33% cheaper with an incremental value of CAD$725.13 compared to un-
treated insomnia and 56% cheaper with an incremental value of $1158.81 com-
pared to benzodiazepines treatments. Cognitive-behavioral therapy was the
clearly in dominance and dominate bezodiazepines with an ICER of -46520 and
untreated insomnia with an ICER of -27251. Monte-carlo probabilistic sensitivity
analysis shows the cognitive behavioral therapy as the optimal strategy with a net
monetary benefit of CAD$30809.40. CONCLUSIONS: This case example using in-
somnia and the risk of falls in the elderly demonstrates that current treatment
reimbursement options that fund pharmacologic but not non-pharmacologic ther-
apy for geriatric insomnia are neither cost-saving nor ethically recommendable
from the health system’s perspective.A major restructuring of decision-making
processes for reimbursement of treatment options for chronic non-life threatening
conditions is required that considers age-related adverse treatment effects
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OBJECTIVES: We conducted a cost-effectiveness analysis (CEA) on two strategies:
routine HIV counseling and testing (RCT) and home-based HCT (HBHCT) in
Kayunga District, Uganda. METHODS: A decision-analytic model was developed to
evaluate the cost-effectiveness of RCT and HBHCT for provision of HCT to the
population between 2008 and 2010. The reference case was a 30-year old woman in
Kayunga District and the provider perspective was adopted. Costs for HCT were
obtained from project records (MUWRP) and the main outcome measure (effective-
ness) was the number of people who got to know their HIV sero-status in the review
period. Data were analyzed using Tree-age Pro 2011®software. RESULTS: Of 68,650
clients who underwent RCT strategy, only 49.7% (34,138) received their HIV test
results. For HBHCT, 45,000 clients were counseled and tested and 70.6% (31,813)
received their HIV test results. The probability of counseling and testing a HIV
positive client was 0.11 for RCT and 0.03 for HBHCT. The unit cost of providing HCT
was $4.39 for RCT and $10.45 for HBHCT. RCT had an incremental cost of $4.60 and
an incremental cost effectiveness ratio of $15.10 per individual offered HCT.
CONCLUSIONS: In this study, RCT was the more cost-effective strategy. However,
HBHCT was more effective in terms of reaching out to more people who get to know
their HIV sero-status. Basing on the findings of this study, RCT should be prioritized
in all health centers while targeting HBHCT for high burden and hard to reach
settings.
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OBJECTIVES: To assess cost-effectiveness of infant vaccination with 10-valent
pneumococcal non-typeable Haemophilus influenzaeprotein-D conjugate vaccine
(PHiD-CV) or 13-valent pneumococcal conjugate vaccine (PCV13) versus no vacci-
nation in Russia. METHODS: The analysis was performed for a 10-year and a life-
time horizons from health care and societal perspectives. In the analysis only the
direct effect of vaccination was assessed. The effect on invasive pneumococcal
diseases (meningitis, bacteriemia), community acquired pneumonia and pneumo-
coccal acute otitis media (AOM) was evaluated for both vaccines. The effect of
PHiD-CV on AOM caused by non-typeable Haemophilus influenzae was also con-
sidered. Medical costs were estimated based on tariffs of obligatory medical insur-
ance in Saint-Petersburg in 2012. Vaccine cost/dose and schedule of infant vacci-
nation (two doses followed by booster dose) were assumed to be the same for both
vaccines. Indirect costs included illness allowance and productivity losses. Costs
and health benefits were discounted at 3.5%/year. Willingness to pay threshold was
assumed as 1 GDP/capita (approximately 380 KRUB). Sensitivity analysis was con-
ducted on main parameters (incidence data, vaccines effectiveness, costs).
RESULTS: The research showed that incremental cost-effectiveness ratios (ICERs)
for both vaccines are very close. Considering health care perspective ICERs for
PHiD-CV and PCV13 were 376.5 and 383.3 KRUB/1 life year gained (LYG) respectively
at 10-year horizon; 89.1 and 91.1 KRUB/1 LYG at a lifetime horizon. Considering
societal perspective ICERs were 312.6 and 333.3 KRUB/LYG for PHiD-CV and PCV13
respectively at 10-year horizon; both vaccines were shown to be dominating alter-
natives at a lifetime horizon. Sensitivity analysis indicated that results were more
sensitive to incidence data and costs. CONCLUSIONS: Vaccination of infants in
Russia with PHiD-CV and PCV13 is cost-effective at a 10-year horizon. PHiD-CV in
base case analysis had a little bigger potential cost offset compared to PCV13. Both
vaccines could be recommended for inclusion in the Russian national immuniza-
tion calendar.
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OBJECTIVES: Treatment with antiepileptic drugs is commonly guided by serum
level monitoring. Such monitoring requires expensive laboratory equipment and
products. However, well-conducted studies on the cost-effectiveness of therapeu-
tic drug monitoring for antiepileptic drugs are lacking particularly in patients with
structural-metabolic epilepsy. Moreover, there are contradictory thoughts on the
importance of using serum-level monitoring to optimise antiepileptic drugs ther-
apy. The study aims to assess the cost-effectiveness of serum level monitoring
services in the management of children diagnosed with structural-metabolic
epilepsy. METHODS: A retrospective cost-effectiveness analysis was conducted
from the provider perspective. It included patients attended a paediatric neurology
clinic. The effectiveness measures used in this analysis were the number of pa-
tients that achieved 50% reduction in seizure frequency, and the number of pa-
tients with 3-month seizure free. Medical records of the patients were reviewed for
the required information. Medical chart/billing data obtained from the hospital
were collected to estimate the resources used. The recruited children were fol-
lowed for one year following their first visit. RESULTS: The average cost effective-
ness ratio for the monitored patients (MYR 2,735 per patient that achieved a 50%
reduction in seizure frequency) was lower than that for non-monitored patients
(MYR 2,921 per patients that achieved a50% reduction in seizure frequency), with
incremental cost-effectiveness ratio of MYR 2,357 per one additional patient that
achieved a 50% reduction in seizure frequency. The average cost effectiveness
ratios for monitored and non-monitored group were MYR 8,279 and MYR 6,433 per
patient with a 3-month seizure-free period, respectively, with incremental cost-
effectiveness ratio of MYR 29,666 per one additional patient with a 3-month sei-
zure-free period. CONCLUSIONS: In terms of the effectiveness measures used,
serum level monitoring of antiepileptic drugs was found to be cost-effective. How-
ever, the incremental cost-effectiveness ratio was found to be sensitive to the cost
of management.
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OBJECTIVES: Universal hepatitis B vaccination policy has not been introduced in
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Japan. In this study, we conducted an economic evaluation of a universal infant
hepatitis B vaccination compared with the current selective strategy of vaccinating
high-risk infants. METHODS: A cost-effectiveness analysis was conducted using a
Markov model. The state transition process was defined as a series of 9 states
including susceptible, immune, acute hepatitis, fulminant hepatitis, asymptom-
atic carrier, chronic hepatitis, liver cirrhosis, hepatocellular carcinoma and death.
All data on cost, epidemiology and utility were derived from official statistics,
published literatures and expert opinion. The incremental cost-effectiveness ratio
(ICER) per quality-adjusted life year gained and life-year gained were calculated at
a 3% discount rate. The analysis was performed from payer’s perspective and time
horizon was set to 100 years. One-way sensitivity analysis was undertaken. All
parameters were projected to the population of 2009 birth cohort, 1.078 million.
RESULTS: By introducing the universal hepatitis B vaccination, 1,507 patients and
197 deaths caused by HBV related liver diseases were expected to be prevented.
Cost of medical care was saved 770 million yen, but the cost of vaccination was 1.77
billion yen. Estimated ICERs were 18,300,515 yen/QALY and 20,093,520 yen/LYG.
When the cost of vaccination was 5,600 yen(1,868 yen per dose), ICER was 5,000,000
yen/QALY.CONCLUSIONS:At a cost of 5,600 yen(1,868 yen per dose) of vaccination,
universal hepatitis B policy was considered to be cost- effective in Japan. In hepa-
titis B, regional differences of genotype were well-known and affected the sequel of
hepatitis B related diseases. Because most of the epidemiological data employed in
this study were derived from foreign literatures, we try to replace then into esti-
mated local data. This study was partially supported by the grant of Japanese
Ministry of Health, Labor and Welfare (Research on Applying Health Technology).
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OBJECTIVES: Anaphylaxis is a severe life threatening acute event that can have a
number of triggers. Specialist services are believed to be important in preventing
recurrence and current lack of referral might mean high recurrence rates and
unnecessary cost. Also, lack of timely and correct use of adrenaline injectors might
lead to significant excess mortality. The study objective was therefore to assess the
cost effectiveness of specialist service versus standard care with or without pre-
scription of adrenaline injectors. METHODS: A Markov model validated by clinical
experts was constructed, which modeled anaphylaxis according to trigger, either
food, drug, insect or idiopathic. Anaphylaxis mortality was modeled as a function
of time to die and time for emergency response. Probabilistic sensitivity analysis on
key parameters was performed. RESULTS: Standard care with injectors was dom-
inated by specialist service with or without injectors. Specialist service with no
injectors would be cost effective if the threshold for a Quality Adjusted Life Year
was greater than about £740 and with injectors would be cost effective if the
threshold was greater than £1800. These results were robust to all sensitivity anal-
yses except at relatively extreme values of a small number of parameters.
CONCLUSIONS: This is the first study to address the cost effectiveness of specialist
service or adrenaline injectors in anaphylaxis. The results showed that specialist
service with adrenaline injectors was cost effective at a threshold of £20,000 per
Quality Adjusted Life Year. More well designed prospective studies on the effec-
tiveness of specialist services are needed to confirm these findings.
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OBJECTIVES: Participation in coronary heart disease (CHD) secondary prevention
programs is low, therefore an innovative program is needed to meet this treatment
gap. As a secondary aim within a large trial, the current study evaluated cost-
effectiveness of a telephone-delivered secondary prevention program for myocar-
dial infarction patients compared to usual care. METHODS: A total of 430 adult
myocardial infarction patients were randomised to a six-month CHD secondary
prevention ‘health coaching’ intervention or usual care condition. Primary out-
come variables were health-related quality of life (SF-36) and physical activity (Ac-
tive Australia Survey). Data were collected at baseline, 6 months (post-interven-
tion) and 12 months (6 months post-intervention). A secondary cost-effectiveness
analysis was conducted. Health utility (SF-6D) and health care utilisation data were
collected using self-reported (GP, specialist, other health professionals, health ser-
vices, and medication) and claims data (hospitalisation rates). Multiple imputation
techniques were applied to adjust for missing data. Intervention effects are pre-
sented as mean difference (95% CI), p value. RESULTS: Improvements in health
status (SF-6D) were observed in both groups, with no significant difference between
the groups at 6 [0.012 (-0.016, 0.041), p0.372] or 12 months [0.011 (-0.028, 0.051)
p0.738]. Patients in the health coaching group were significantly more often ad-
mitted to hospital due to causes not related to cardiovascular disease (p0.042).
The overall cost for the health coaching group was higher ($10,574 vs. $8,534,
p0.021), mainly due to higher hospitalisation costs ($6,841 vs. $4,984, p0.036).
The incremental cost-effectiveness ratio was $85,423 per QALY. CONCLUSIONS:
ProActive Heart is not a cost-effective intervention compared to usual care. There
was no intervention effect on SF-6D at 6 or 12 months and it resulted in signifi-
cantly increased costs. This higher cost may in the future eventuate in cost savings,
as patients are better monitored and health problems may be identified at an
earlier stage resulting in better health outcomes.
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OBJECTIVES: To assess the cost-effectiveness of rotigotine transdermal patch rel-
ative to placebo and oral dopamine agonists (ropinirole and pramipexole) in the
treatment of moderate-to-severe idiopathic restless legs syndrome (RLS) from the
perspective of National Health Service (NHS) Scotland. METHODS: A cost-utility
analysis was conducted using a decision tree in order to measure the cost per
quality-adjusted life-year (QALY) gained resulting from the treatment of moderate-
to-severe idiopathic RLS in 2008. Clinical, safety and quality of life data were ex-
tracted from the literature. The decision analytic model was run for a 1-year time
horizon in the base-case analysis. The model included direct medical costs, aug-
mentation rate and the most common adverse events. Sensitivity analyses as-
sessed the effect of varying the time horizon to 9 months, 2 and 5 years. An annual
discount rate of 3.5% was applied to costs and benefits for analysis beyond 1 year.
RESULTS: Over a 1-year period, treating patients with rotigotine would result in a
total cost of £1658 per patient as compared with £606, £1152 and £1055 for placebo,
ropinirole and pramipexole respectively. Treatment with rotigotine resulted in
0.842 QALYs gained compared with 0.691 for placebo, 0.753 for ropinirole and 0.780
for pramipexole. The cost per QALY gained for rotigotine was £6990 versus placebo,
£5725 versus ropinirole and £9729 versus pramipexole. Probabilistic sensitivity
analysis has shown that the probability of rotigotine being cost-effective compared
with placebo, ropinirole and pramipexole is greater than 0.90 at a willingness to pay
threshold of £13,000. At a threshold of £20,000, the probability of rotigotine being
more cost-effective is close to 1 versus placebo and ropinirole and 0.93 versus
pramipexole. CONCLUSIONS: Rotigotine transdermal patch was shown to be a
cost-effective treatment in patients with moderate-to-severe restless legs syn-
drome from the payer’s perspective (NHS Scotland).
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OBJECTIVES: To evaluate the cost-effectiveness of tolvaptan for hypervolemic or
euvolemic hyponatremia in South Korea. METHODS: A decision tree was con-
structed to assess the clinical and economic impact over 30 days from restricted
societal perspective. A competitor was supportive care. The result was presented
as the incremental cost per QALY gained. We supposed that patients would move
to 3 different serum sodium levels; normonatremia (135mEq/L), mild hyponatre-
mia (130-135mEq/L), marked hyponatremia(130 mEq/L) after 4 days treatment.
Each level had three states; discharge, continuing hospitalization and death. Ac-
cording to serum sodium level, Patients had difference their length of hospital stay.
Uncertainty was explored with deterministic sensitivity analysis. RESULTS: The
analysis showed that cost of tolvaptan was 1,358,370 KRW and supportive care was
1,396,092 KRW. The use of tolvaptan reduced 37,722 KRW for supportive care.
QALYs were 0.047203, 0.042146 (tolvaptan, supportive care, respectively). Tolvap-
tan had 0.00506 QALYs higher. Cost-effectiveness analysis represented tolvaptan
was dominant. The deterministic sensitivity analysis for uncertain parameters
demonstrated that this analysis results were robust. CONCLUSIONS: Tolvaptan
was cost-effective for hyponatremia in comparison with supportive care. The first
medicine as oral vasopressin receptor antagonist, tolvaptan could increase pa-
tients’ quality of life for hyponatremia in Korean population.
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OBJECTIVES: Estimation of indirect and selected direct costs of hypoglycaemia in
patients with type 1 and type 2 diabetes in Poland. METHODS: The study was
conducted at 4 Polish diabetes centres- 2 urban and 2 suburban. Anonymous ques-
tionnaire comprising 35 questions was used in direct interviews. Data were anal-
ysed in a population of 180 patients with diagnosed diabetes who experienced
severe (requiring third party support) or/ and non-severe hypoglycaemia during
last year. Indirect costs were estimated using a human capital approach based on
lost Gross Domestic Product (GDP) and lost gross earnings. Additional estimations
of direct costs, which could be attributed to hypoglycaemic event, were based on
used medical resources and their unit prices. RESULTS: There were on average 0.16
episodes of severe and 4.66 episodes of non- severe hypoglycaemia per patient in
the recall period (1month). An average total monthly cost of severe hypoglycaemia
was 699.77 EUR, with hospitalisation being a main cost driver, and 40 EUR in the
case of a non-severe episode. 23% of the studied population was professionally
active. A total average time lost was equal to 3.85 hours, which in Polish conditions
gave an absenteeism cost per month of 16.27 EUR (GDP lost) and 16.99 EUR (lost
earnings) per person per month. 52.38% of employed patients reported reduced
productivity while at work (presenteism). Its value was estimated at the level of
14.88 EUR and 15.53 EUR per patient per episode according to GDP and earnings lost
respectively. Indirect costs related to sick-leaves and hospitalisations in working-
age population were not reported in the study. CONCLUSIONS: Hypoglycaemic
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